1700015E13Rik Inhibitors
Chemical inhibitors of protein 1700015E13Rik can impede its activity through various molecular mechanisms, each involving the interruption of specific signaling pathways and phosphorylation events. Staurosporine, a broad-spectrum protein kinase inhibitor, can prevent the activation of protein 1700015E13Rik by obstructing the action of kinases required for its phosphorylation. Similarly, LY294002 and Wortmannin are both inhibitors of PI3K, a kinase involved in signaling pathways that lead to the activation of protein 1700015E13Rik. By inhibiting PI3K, these chemicals reduce the phosphorylation and activation of the protein. Rapamycin, on the other hand, targets the mTOR pathway, which has a role in protein synthesis and the activation of protein 1700015E13Rik. By impeding mTOR, Rapamycin can suppress the pathways that contribute to the protein's functionality.
Additional inhibitors target the MAPK pathway, which includes the MEK-ERK and the p38 MAP kinase cascades, both of which are implicated in the activation of protein 1700015E13Rik. PD98059 and U0126 are selective inhibitors of MEK1 and MEK2, leading to the inhibition of ERK and subsequently reducing the activation of protein 1700015E13Rik. SB203580 specifically inhibits p38 MAP kinase, which can decrease the phosphorylation level and activity of the protein. Another inhibitor, SP600125, impedes JNK, which is involved in stress response pathways that could regulate the activity of protein 1700015E13Rik. Src family kinases, which phosphorylate a variety of substrates that may regulate protein 1700015E13Rik, can be inhibited by PP2 and Dasatinib, thus diminishing the protein's activity. Y-27632 inhibits ROCK, which has implications for the actin cytoskeleton and may affect protein 1700015E13Rik activity. Lastly, Palbociclib inhibits CDK4/6 kinases, which can regulate the cell cycle and possibly the activity of protein 1700015E13Rik, leading to a reduction in its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine can inhibit protein kinases that are crucial for the phosphorylation events necessary for 1700015E13Rik activity. By blocking these kinases, it prevents the phosphorylation and subsequent activation of 1700015E13Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 specifically inhibits PI3K, which is involved in a pathway that activates 1700015E13Rik. Inhibition of PI3K leads to a reduction in the phosphorylation events necessary for 1700015E13Rik to become functionally active. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that can disrupt the PI3K-dependent signaling pathway, thereby reducing the activation of downstream proteins such as 1700015E13Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is potentially involved in the activation of 1700015E13Rik. By inhibiting mTOR, the protein synthesis and activation pathways that contribute to 1700015E13Rik function are suppressed. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 specifically inhibits MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 prevents the activation of ERK that may be necessary for the phosphorylation and activation of 1700015E13Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2, which prevents the phosphorylation and activation of ERK. Since ERK may be involved in the activation of 1700015E13Rik, its inhibition by U0126 results in reduced function of 1700015E13Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAP kinase, which is implicated in the stress response and may be involved in the activation of 1700015E13Rik. Inhibition of p38 MAP kinase by SB203580 would lead to decreased phosphorylation and activity of 1700015E13Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of JNK, which participates in cellular stress responses. Inhibition of JNK can lead to reduced activity of proteins that are regulated by stress-activated pathways, including 1700015E13Rik. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a Src family kinase inhibitor. Src kinases can phosphorylate various substrates that may be involved in the regulation or activation of 1700015E13Rik. By inhibiting Src kinases, PP2 can therefore reduce the activity of 1700015E13Rik. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, can inhibit Src family kinases as well as BCR-ABL tyrosine kinase which could be involved in the phosphorylation and subsequent activation of 1700015E13Rik. | ||||||